Endocalyx in Treatment Resistent Hypertension

Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

About this trial

The goal of this randomized, double-blind, placebo-controlled study is to assess whether the food supplement Endocalyx lowers blood pressure in patients with treatment resistant hypertension.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Treatment resistant hypertension defined as

an uncontrolled office BP (≥140/90 mmHg).

is on a regimen of ≥3 adequately dosed antihypertensive agents of different classes, including a diuretic, at maximum tolerated dose based on investigator judgment.

Stable diuretic and antihypertensive treatment for the previous 3 weeks.

Disqualifiers

Age <18 years.

Estimated glomerular filtration rate (eGFR) <20 ml/min/1.73m2 measured by the 2021 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine formula and the 2012 cystatin C CKD-EPI formula.

A mean seated systolic blood pressure of at least 180 mmHg or a diastolic blood pressure of at least 110 mmHg.

Known secondary hypertension

Trial design

Design model

Parallel

Treatments tested in this trial

  • Endocalyx Pro

    Dietary supplement

    4 capsules once daily OR 2 capsules twice daily

  • Placebo

    Other intervention

    4 capsules once daily OR 2 capsules twice daily

Treatment groups

64 Participants
are divided into 2 treatment groups
Group A: Endocalyx ProExperimental treatment 1 intervention
Group B: PlaceboPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Change from baseline in 24-hour systolic blood pressure

We will perform an uncorrected analysis and an analysis that is corrected for the reported and measured changes in antihypertensive medication use.

Time frame
12 weeks

Secondary outcomes

1

Change from baseline in 24-hour diastolic blood pressure

Time frame
12 weeks
2

Change from baseline in seated systolic office blood pressure

Time frame
12 weeks
3

Change from baseline in seated diastolic office blood pressure

Time frame
12 weeks
4

Change from baseline in percentage of patients with a night-time blood pressure dip

The nighttime blood pressure dipping status will be measured with a 24-hour blood pressure measurements. Patients will be classified as a 'dippers' when the nighttime systolic blood pressure and/or diastolic blood pressure falls \>10% and \<20% compared to daytime readings. Exteme dippers are described as those with blood pressure fall of at least 20%. Patients with blood pressure fall between 0 and 10% are classified as non-dippers.

Time frame
12 weeks

Other outcomes

1

To assess whether sodium intake, measured using 24-hour urine collection, modulate the effect of Endocalyx on blood pressure.

We will study the (possible) modulatory effect sodium intake (mmol/L), measuring using 24 hours urine collection, on the effect of endocalyx on blood pressure.

Time frame
12 weeks
2

To assess whether sex modulate the effect of Endocalyx on blood pressure.

The association between sex and the effect of endocalyx on blood pressure.

Time frame
12 weeks
3

To assess whether kidney function modulate the effect of Endocalyx on blood pressure.

The association between kidney function and the effect of endocalyx on blood pressure.

Time frame
12 weeks

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Lead sponsor

Dutch Heart Foundation

Collaborator

Dutch Kidney Foundation

Collaborator

Microvascular Health Solutions LLC

Collaborator